These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 18281442

  • 1. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen.
    Galanello R, Piga A, Cappellini MD, Forni GL, Zappu A, Origa R, Dutreix C, Belleli R, Ford JM, Rivière GJ, Balez S, Alberti D, Séchaud R.
    J Clin Pharmacol; 2008 Apr; 48(4):428-35. PubMed ID: 18281442
    [Abstract] [Full Text] [Related]

  • 2. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects.
    Séchaud R, Robeva A, Belleli R, Balez S.
    J Clin Pharmacol; 2008 Aug; 48(8):919-25. PubMed ID: 18508948
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks.
    Séchaud R, Dutreix C, Balez S, Pommier F, Dumortier T, Morisson S, Brun E.
    Int J Clin Pharmacol Ther; 2008 Feb; 46(2):102-8. PubMed ID: 18218291
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R, Campus S, Origa R.
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE, Hagemann TM.
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
    Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann AK, Grant FD, Paley C, Shannon M, Neufeld EJ.
    Blood; 2009 Nov 05; 114(19):4009-13. PubMed ID: 19724055
    [Abstract] [Full Text] [Related]

  • 9. The palatability and tolerability of deferasirox taken with different beverages or foods.
    Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E.
    Pediatr Blood Cancer; 2013 Sep 05; 60(9):1507-12. PubMed ID: 23637051
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB.
    Drug Metab Dispos; 2010 May 05; 38(5):808-16. PubMed ID: 20097723
    [Abstract] [Full Text] [Related]

  • 11. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
    Miyazawa K, Ohyashiki K, Urabe A, Hata T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H, Rojkjaer L, Omine M.
    Int J Hematol; 2008 Jul 05; 88(1):73-81. PubMed ID: 18597054
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacology of deferasirox.
    Tanaka C.
    Clin Pharmacokinet; 2014 Aug 05; 53(8):679-94. PubMed ID: 24996374
    [Abstract] [Full Text] [Related]

  • 13. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F, Puntoni M, Marini V, Fucile C, Milano G, Robbiano L, Perrotta S, Pinto V, Martelli A, Forni GL.
    Eur J Haematol; 2015 Apr 05; 94(4):310-7. PubMed ID: 25081908
    [Abstract] [Full Text] [Related]

  • 14. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A, Stark JG, Pixton GC, Sommerville KW, Zamora CA, Leibowitz M, Rolleri R.
    Clin Ther; 2012 Jul 05; 34(7):1601-12. PubMed ID: 22717418
    [Abstract] [Full Text] [Related]

  • 15. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S, De Francia S, Cusato J, Pirro E, Massano D, Piga A, D'Avolio A.
    J Pharm Pharmacol; 2016 Nov 05; 68(11):1417-1421. PubMed ID: 27672004
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oral bioavailability of ospemifene improves with food intake.
    Koskimies P, Katila K, Lammintausta R, Aaltonen AM, Vuorinen J, Saarni O, Scheinin M.
    Int J Clin Pharmacol Ther; 2013 Oct 05; 51(10):787-94. PubMed ID: 24040848
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
    Chauzit E, Bouchet S, Micheau M, Mahon FX, Moore N, Titier K, Molimard M.
    Ther Drug Monit; 2010 Aug 05; 32(4):476-81. PubMed ID: 20386360
    [Abstract] [Full Text] [Related]

  • 20. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
    Lincoln J, Stewart ME, Preskorn SH.
    J Psychiatr Pract; 2010 Mar 05; 16(2):103-14. PubMed ID: 20511734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.